Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.